By Bruce Buckley
Two studies presented at the ESC Congress 2017, in Barcelona, Spain, this past week found that apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) is superior to other oral anticoagulants in lowering the risk for stroke/systemic embolism (SE) and in reducing the rate of major bleeding in patients with nonvalvular atrial fibrillation (NVAF).
In one study, the researchers analyzed pooled patient data from four major U.S. sources—Optum, MarketScan, PharMetrics and Humana—to